Dr. Jennifer Buell (President, CEO & Director) reiterated MiNK’s differentiation as “an off the shelf” allogeneic iNKT platform that is “administered without lymphodepletion, without HLA matching,” ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results